<DOC>
	<DOC>NCT01150500</DOC>
	<brief_summary>The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.</brief_summary>
	<brief_title>RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries</brief_title>
	<detailed_description>The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Acceptable candidate for percutaneous coronary intervention (PCI),stenting, and emergency coronary artery bypass graft surgery Clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia and/or positive functional study Informed consent Patient agrees to comply with specified followup evaluations at same investigational site Single target lesion or two target lesions located in separate coronary arteries De novo lesion(s) in native coronary artery(ies) Target lesion(s) ≤ 27 mm in length Target vessel(s) have reference vessel diameter 2.25 mm to 3.5 mm Within 7 days of implant platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³; White Blood Cell (wbc) count &lt;3,000 cells/mm³; serum creatinine level &gt;2.5 mg/dl Acute myocardial infarction (MI) within 72 hrs of the index procedure (Q wave myocardial infarction(QWMI)/non Q wave myocardial infarction (NQMI) or any elevation of creatinine kinease myocardialband isoenzyme(CKMB) &gt; lab upper limit of normal) Previous PCI of target vessel(s) within 9 months prior to the procedure Planned PCI of any vessel within 30 days postindex procedure and/or planned PCI of target vessel(s) within 12 months postindex procedure History of stroke or transient ischemic attack(TIA) within prior 6 months Participating in investigational drug/device study that has not completed primary endpoint or interferes with study endpoints Inability to comply with required trial antiplatelet regimen Previous stent in target vessel unless it has been at least 9 months since stent placed and target lesion(s) is/are at least 15 mm from previous stent Target vessel(s) has/have other lesions w/ &gt; 40% diameter stenosis Unprotected left main coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Medtronic</keyword>
	<keyword>Japan</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Small Vessel Stent</keyword>
</DOC>